Inspection Findings in Pharmacovigilance

Introduction

Inspection findings are the primary outputs of pharmacovigilance inspections.

They represent deficiencies, weaknesses or concerns identified by regulatory authorities during inspection activities.

Inspection findings are important because they provide insight into:

• Compliance effectiveness
• Governance maturity
• Risk management capability
• System control
• Patient safety protection

The significance of a finding extends beyond the specific issue identified.

Inspectors often view findings as indicators of broader system performance.

What Is an Inspection Finding?

An inspection finding is a documented observation made by inspectors when evidence indicates that:

• Regulatory requirements are not met.
• Processes are ineffective.
• Controls are insufficient.
• Responsibilities are unclear.
• Risks are inadequately managed.

Findings are evidence-based.

Inspectors typically support findings through:

• Documentation review
• Interviews
• Operational records
• System demonstrations

The quality of evidence often determines the strength of the finding.

Why Inspection Findings Matter

Inspection findings influence regulatory confidence.

A finding may indicate:

• A local issue
• A process weakness
• A governance failure
• A systemic compliance problem

Inspectors often assess not only the issue itself but also what the issue reveals about the wider pharmacovigilance system.

A useful principle is:

Findings are often symptoms of deeper governance or oversight weaknesses.

Finding Classification

Most authorities classify findings according to significance.

Although terminology varies, classifications commonly include:

Critical Findings

Highest level of regulatory concern.

Major Findings

Significant deficiencies requiring prompt remediation.

Minor Findings

Lower-risk deficiencies requiring correction.

Classification influences regulatory expectations and follow-up activities.

Critical Findings

Critical findings are the most serious category.

They generally indicate situations involving:

• Significant patient safety risk
• Significant public health risk
• Major regulatory non-compliance
• Fundamental control failures

Examples may include:

• Failure to report serious adverse reactions
• Absence of effective pharmacovigilance systems
• Significant data integrity failures
• Failure to implement required risk minimisation measures

Critical findings frequently trigger enhanced regulatory scrutiny.

Major Findings

Major findings indicate significant weaknesses that require management attention.

Examples may include:

• Systemic reporting delays
• Inadequate vendor oversight
• Significant CAPA failures
• Persistent governance deficiencies

Major findings may not create immediate patient safety concerns but often indicate important compliance risks.

Minor Findings

Minor findings generally involve lower-risk deficiencies.

Examples may include:

• Documentation inconsistencies
• Localised procedural deviations
• Isolated record management issues

Although less serious individually, multiple minor findings may indicate broader weaknesses.

Systemic Findings

One of the most important concepts in inspections is systemic impact.

Inspectors often distinguish between:

Isolated Issues

Limited to a specific activity.

Systemic Issues

Affect multiple processes or organisational areas.

Systemic findings typically attract greater attention because they suggest broader control weaknesses.

Repeat Findings

Repeat findings are often viewed seriously by regulators.

A repeat finding may indicate:

• Ineffective CAPAs
• Weak root cause analysis
• Poor governance
• Limited organisational learning

Inspectors frequently explore recurring deficiencies in detail.

A useful principle is:

A repeated finding often attracts greater concern than the original finding.

Root Causes Behind Findings

Findings rarely occur in isolation.

Underlying causes may include:

Governance Weaknesses

Oversight mechanisms are ineffective.

Resource Constraints

Insufficient personnel or expertise.

Training Deficiencies

Responsibilities are not understood.

Process Design Issues

Controls are inadequate.

Technology Limitations

Systems fail to support compliance.

Effective remediation requires understanding these underlying causes.

Regulatory Expectations Following Findings

Following inspection completion, organisations are generally expected to:

• Evaluate findings
• Perform root cause analysis
• Develop CAPAs
• Implement corrective actions
• Verify effectiveness

The quality of the response often influences regulatory confidence.

CAPAs and Inspection Findings

Inspection findings typically require CAPAs.

Strong CAPAs demonstrate:

Understanding

The issue is understood fully.

Root Cause Analysis

Underlying causes are identified.

Appropriate Actions

Remediation is proportional to risk.

Effectiveness Verification

Improvement can be demonstrated.

Weak CAPAs frequently lead to recurring findings.

For additional discussion see:

[[inspection-capas]]

Inspection Findings and the QPPV

The QPPV typically plays an important role in finding management.

Particularly important areas include:

• Significant findings
• Critical findings
• Root cause analysis
• CAPA oversight
• Regulatory communication

Inspectors often evaluate whether significant findings are visible to pharmacovigilance leadership.

Inspection Findings and Vendors

Outsourced activities frequently contribute to inspection findings.

Examples include:

• Weak oversight
• Poor SDEA management
• Inadequate auditing
• Limited governance visibility

Importantly:

Outsourcing activities does not outsource responsibility.

Marketing Authorisation Holders remain accountable for pharmacovigilance compliance.

Inspection Findings and the PSMF

The PSMF frequently contributes to inspection observations.

Common issues include:

• Outdated information
• Missing information
• Inconsistent information
• Inaccurate system descriptions

Inspectors often compare the PSMF against operational reality.

Discrepancies frequently attract attention.

Common Finding Themes

Across inspection programmes, recurring themes often include:

Weak Governance

Poor Vendor Oversight

Limited QPPV Visibility

Weak CAPA Programmes

Inadequate Auditing

Documentation-Reality Gaps

These themes appear consistently across many inspections.

Regulatory Impact of Findings

The impact of findings depends upon:

• Severity
• Scope
• Recurrence
• Risk
• Organisational response

Potential consequences may include:

• CAPA commitments
• Follow-up inspections
• Enhanced oversight
• Increased regulatory scrutiny

Strong responses often reduce long-term regulatory concern.

Characteristics of Effective Finding Management

High-performing organisations generally demonstrate:

Rapid Assessment

Issues are evaluated promptly.

Strong Root Cause Analysis

Underlying causes are identified.

Effective CAPAs

Actions address causes rather than symptoms.

Executive Visibility

Significant issues receive management attention.

Continuous Learning

Findings improve the system.

These characteristics strengthen regulatory confidence.

Key Takeaways

• Inspection findings identify deficiencies observed during regulatory inspections.
• Findings frequently reflect broader governance and oversight issues.
• Critical, major and minor findings represent different levels of regulatory concern.
• Repeat findings often attract significant attention.
• Root cause analysis is essential.
• CAPA quality strongly influences regulatory confidence.
• QPPVs should maintain visibility regarding significant findings.
• Effective organisations use findings to strengthen the pharmacovigilance system rather than simply close observations.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
4. Regulation (EC) No 726/2004.
5. Directive 2001/83/EC.
6. Commission Implementing Regulation (EU) No 520/2012.
7. ICH Q9 Quality Risk Management.
8. ICH Q10 Pharmaceutical Quality System.
9. PIC/S Guidance on Pharmacovigilance Inspections.